Moore H, Dubes L, Fusillo S, et al. - Findings offer encouraging evidence for tofacitinib’s (a selective Janus kinase inhibitor) efficacy and safety as a component of the treatment paradigm for young people with moderate-to-severe inflammatory bowel disease (IBD).

• A single-center retrospective study of people ages 21 years and younger who initiated tofacitinib for medically refractory IBD.

• Tofacitinib was administered to 21 patients, 18 with ulcerative colitis or indeterminate IBD.

• Rapid clinical response to tofacitinib along with its sustained efficacy was seen in nearly half of patients.

• At the end of the 12-week induction span, clinical response was evident in 9 out of 21 (42.9%) patients and steroid-free remission was achieved in 7 out of 21 (33.3%).

• Among evaluable patients at 52 weeks, clinical response and steroid-free remission were achieved in 7 out of 17 (41.2%).

• In pediatric IBD, there exists limited experience with tofacitinib.